Moderate

Sreeram Reddy Vanga, Dr. Lalitha Palle, and Kartikeya Kabra are Season 4's most family-connected health-tech founders from Hyderabad. Sreeram and Dr. Lalitha are siblings, and Kartikeya is Sreeram's brother-in-law, creating a tight-knit founding team bound by family trust and complementary capabilities: Sreeram's business acumen, Dr. Lalitha's medical and scientific expertise, and Kartikeya's marketing and partnership skills. Dr. Lalitha's medical background is the founding team's most commercially critical asset: in a supplement category plagued by unsubstantiated claims and pseudoscience, having a physician co-founder who can explain the exact enzymatic mechanism (alpha-amylase and alpha-glucosidase inhibition) through which Calorie Crusher reduces carbohydrate absorption provides the specific scientific credibility that investors and consumers demand.

Moderate's Calorie Crusher Tablets use a pharmacologically established mechanism to reduce carbohydrate absorption: the tablets contain natural enzyme inhibitors that block alpha-amylase (which breaks starches into maltose) and alpha-glucosidase (which breaks maltose into glucose), preventing up to 40% of dietary carbohydrates from being digested and absorbed. The undigested carbohydrates pass through the digestive system, effectively reducing caloric intake from carbohydrate-heavy meals without requiring dietary restriction. This mechanism is not novel in pharmaceutical science: prescription drugs like Acarbose (used to treat Type 2 diabetes) work on the same principle. Moderate's innovation is packaging this mechanism in a consumer-accessible supplement format rather than a prescription medication, making enzyme inhibition available to health-conscious consumers without a doctor's prescription.

Amount Asked: ₹50 lakhs Equity Offered: 1.25% Implied Pre-Money Valuation: ₹40 crore

Sreeram, Dr. Lalitha, and Kartikeya walked into Season 4 Episode 33 with the most scientifically detailed health supplement pitch of the season. Dr. Lalitha's explanation of the enzymatic mechanism (alpha-amylase and alpha-glucosidase inhibition) transformed the pitch from a supplement sales presentation into a biochemistry lesson that impressed some Sharks and confused others. The Sharks' reactions were Season 4's most dramatically polarised: Vineeta Singh admired the sleek packaging (calling it "exceptionally well done") but admitted to being genuinely scared of trying the product: "Darr lag raha hai, par mann bhi kar raha hai khane ka" (I'm scared, but I'm also tempted to try it). She ultimately exited on safety concerns, unable to personally endorse a product she was afraid to consume.

Vineeta Singh admired the packaging but was genuinely scared of consuming the product: "Darr lag raha hai, par mann bhi kar raha hai." Peyush Bansal expressed initial scepticism and exited. He wished the founders luck but could not construct an investment thesis around a supplement with unresolved safety perception challenges. Anupam Mittal was not sold on the pitch and opted out, seeing insufficient evidence of long-term product safety and market readiness. Aman Gupta was the most entertained Shark: "Thank you for the science class. As a commerce student, maza aa gaya."He praised the science-driven approach and sleek branding, offering ₹50 lakhs for 2.5% equity. Kunal Bahl was initially critical of the packaging but recognised the massive market opportunity. He offered ₹1 crore for 5% equity and combined with Aman after the founders' counter-offer.

Season 4 Episode 33's most scientifically debated health deal. Founders asked ₹50L for 1.25% (₹40 crore). Vineeta, Peyush, and Anupam exited on safety/scepticism. Aman offered ₹50L for 2.5%. Kunal offered ₹1 crore for 5%. Founders countered at ₹1 crore for 3.3%, wanting both Aman and Kunal. After negotiation, Aman and Kunal combined: ₹1 crore for 5% equity at ₹20 crore valuation. The founders received 2x their capital ask (₹1 crore versus ₹50 lakhs) at a 50% valuation markdown (₹40 crore to ₹20 crore), securing two Sharks whose combined consumer brand marketing (Aman) and marketplace scaling (Kunal) expertise could accelerate Moderate's consumer adoption.

Sreeram Reddy Vanga, Dr. Lalitha Palle, and Kartikeya Kabra accepted the two-Shark deal from Aman Gupta and Kunal Bahl at ₹1 crore for 5% equity, valuing Moderate at ₹20 crore. The deal brought boAt's consumer D2C marketing playbook (Aman) and Snapdeal/Titan Capital's marketplace scaling and health-tech investment expertise (Kunal) into Hyderabad's most science-backed lifestyle disease supplement brand, the most commercially relevant two-Shark combination for a consumer health product that needs both mass-market awareness and scientific credibility.

"We will use the funding to fuel hyper-targeted marketing campaigns, including collaborations and partnerships with experts to build awareness about the products and educate consumers on how and why our products work, not just that they work, because trust begins with transparency." — Kartikeya Kabra Moderate continues building from Hyderabad with Aman and Kunal's investment, Huma Qureshi's celebrity evangelism, and the scientific credibility of Dr. Lalitha's medical background. The ₹1 crore investment is being deployed across three priorities: expert collaborations (partnering with nutritionists, diabetologists, and fitness professionals who can scientifically endorse the products), consumer education campaigns (explaining the enzyme inhibition mechanism so consumers understand how, not just that, the products work), and digital marketing (reaching India's 101 million diabetics and 135 million pre-diabetics through targeted health content).